From Promise to Proof: Personalized Melanoma mRNA Vaccine Delivers Phase III Success

October 26, 2026 by

Just a few years ago, millions of people received messenger RNA (mRNA) COVID-19 vaccines, a breakthrough made possible in part by decades of research established by oncology scientists studying mRNA technology. Now, in a remarkable full circle moment, that same platform that delivered COVID-19 vaccines in record time in 2021 is delivering yet another impressive feat: a personalized mRNA vaccine for melanoma that produced positive phase III results.

mRNA is a molecule that carries instructions for cells to make proteins. In the case of the investigational cancer vaccine intismeran autogene (previously known as mRNA-4157/V940), instructions are delivered for producing neoantigens, proteins arising from mutations unique to a patient’s tumor. This personalized approach trains T cells to target cancer cells bearing these features. To help sustain the immune response, the vaccine is given in combination with pembrolizumab (Keytruda), a type of immune checkpoint inhibitor that has been approved for more than 20 different cancer types, which works by blocking the programmed death ligand 1 (PD-1) immune checkpoint.

For many patients with melanoma, outcomes are dramatically improving due to progress in surgery, immunotherapy, and targeted therapy. Despite these advancements, those with high-risk disease are at an increased risk of recurrence. The persistent threat of relapse continues to drive the search for new approaches that can deliver more durable protection against the disease.

Phase III trial results showed that a personalized mRNA vaccine plus immunotherapy reduced the risk of disease recurrence in patients with high-risk melanoma.

Enter the use of this personalized mRNA cancer vaccine. When combined with pembrolizumab, intismeran autogene reduced the risk of disease recurrence in patients with high-risk melanoma in a phase III clinical trial, according to new results presented at the European Society for Medical Oncology (ESMO) Congress 2026.

The phase III INTerpath-001 clinical trial enrolled 1,1137 patients with stage 2B-4 melanoma whose tumors had been surgically removed. Patients received pembrolizumab and either the personalized vaccine or a placebo. After a median follow up 24.6 months, the combination reduced the risk of recurrence or death by 42% and the risk of distant metastasis or death by 38% compared to pembrolizumab alone. No new safety concerns were observed compared to previously reported studies of the combination, and the trial is ongoing with continued evaluation of overall survival.

The findings build on earlier phase II results presented at the AACR Annual Meeting 2023, which demonstrated improved recurrence-free survival and provided evidence that patients could benefit regardless of the status of several biomarkers. Five-year follow-up data from that trial, presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2026, suggest that the vaccine plus pembrolizumab may help patients live longer compared with pembrolizumab alone, but the analysis was based on limited data and did not definitely demonstrate an overall survival benefit.

“Everyone is very hopeful that this will be a new way to treat patients with melanoma,” said Robert H. Vonderheide, MD, DPhil, FAACR, director of the Abramson Cancer Center of the University of Pennsylvania and AACR President-Elect, in an interview. He noted that the results of this study should be considered one of our biggest breakthroughs to date.

Intismeran autogene in combination with pembrolizumab is currently being tested in other cancer types including non-small cell lung cancer, renal cell carcinoma, and bladder cancer, while similar vaccines are being investigated in pancreatic cancer and glioblastoma. Although more research is needed, these personalized vaccines could redefine standard of care by providing patients with a tailored, highly effective strategy to prevent recurrence and achieve long-lasting remission.